High numbers of CD68+ tumor-associated macrophages correlate with poor prognosis in extranodal NK/T-cell lymphoma, nasal type

Annals of Hematology

Volumn 94, Issue 9, 2015, Pages 1535-1544

  Wang, Hua ^a,b   Li, Pengfei ^a,b   Wang, Liang ^a,b   Xia, Zhongjun ^a,b   Huang, HuiQiang ^a,b   Lu, Yue ^a,b   Li, ZhiMing ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Department of Colorectal Surgery   (China)

Author keywords

CD68; Extranodal NK T cell lymphoma; Nasal type; Prognosis; Tumor associated macrophages

Indexed keywords

ASPARAGINASE; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; KI 67 ANTIGEN; OXALIPLATIN; PREDNISONE; VINCRISTINE; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC INDEX; LOW RISK PATIENT; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; AGED; BLOOD; DISEASE FREE SURVIVAL; LEUKOCYTE COUNT; LYMPHOMA, EXTRANODAL NK-T-CELL; MACROPHAGE; METABOLISM; MIDDLE AGED; MORTALITY; NOSE NEOPLASMS; SURVIVAL RATE;

AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKOCYTE COUNT; LYMPHOMA, EXTRANODAL NK-T-CELL; MACROPHAGES; MALE; MIDDLE AGED; NOSE NEOPLASMS; SURVIVAL RATE;

EID: 84938742710     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2401-4     Document Type: Article

References (40)

1. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C (2007) Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 121(11):2381–2386. doi:10.1002/ijc.23192
2. Joyce JA (2005) Therapeutic targeting of the tumor microenvironment. Cancer Cell 7(6):513–520. doi:10.1016/j.ccr.2005.05.024
3. Komohara Y, Niino D, Ohnishi K, Ohshima K, Takeya M (2015) Role of tumor-associated macrophages in hematological malignancies. Pathol Int. doi:10.1111/pin.12259
4. Chanmee T, Ontong P, Konno K, Itano N (2014) Tumor-associated macrophages as major players in the tumor microenvironment. Cancers 6(3):1670–1690. doi:10.3390/cancers6031670
5. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A (2008) Macrophage polarization in tumour progression. Semin Cancer Biol 18(5):349–355. doi:10.1016/j.semcancer.2008.03.004
6. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD (2010) Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362(10):875–885. doi:10.1056/NEJMoa0905680
7. Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, Steidl C, Gordon LI, Horning SJ, Gascoyne RD (2012) Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 120(16):3280–3287. doi:10.1182/blood-2012-04-421057
8. Agur A, Amir G, Paltiel O, Klein M, Dann EJ, Goldschmidt H, Goldschmidt N (2014) CD68 staining correlates with the size of residual mass but not with survival in classical Hodgkin lymphoma. Leuk Lymphoma:1–5. doi:10.3109/10428194.2014.963081
9. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351(21):2159–2169. doi:10.1056/NEJMoa041869
10. Alvaro T, Lejeune M, Camacho FI, Salvado MT, Sanchez L, Garcia JF, Lopez C, Jaen J, Bosch R, Pons LE, Bellas C, Piris MA (2006) The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica 91(12):1605–1612
11. Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, Lamy T, Sonet A, Rousselet MC, Foussard C, Xerri L (2008) High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol: Off J Am Soc Clin Oncol 26(3):440–446. doi:10.1200/jco.2007.12.8298
12. de Jong D, Koster A, Hagenbeek A, Raemaekers J, Veldhuizen D, Heisterkamp S, de Boer JP, van Glabbeke M (2009) Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 94(1):70–77. doi:10.3324/haematol.13574
13. Cai QC, Liao H, Lin SX, Xia Y, Wang XX, Gao Y, Lin ZX, Lu JB, Huang HQ (2012) High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma. Med Oncol (Northwood, London, England) 29(4):2317–2322. doi:10.1007/s12032-011-0123-6
14. Yamamoto W, Nakamura N, Tomita N, Takeuchi K, Ishii Y, Takahashi H, Watanabe R, Takasaki H, Motomura S, Kobayashi S, Yokose T, Ishigatsubo Y, Sakai R (2014) Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study. Leuk Lymphoma 55(12):2721–2727. doi:10.3109/10428194.2014.893311
15. Kridel R, Steidl C, Gascoyne RD (2015) Tumor-associated macrophages in diffuse large B-cell lymphoma. Haematologica 100(2):143–145. doi:10.3324/haematol.2015.124008
16. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO, Liang R (2009) Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 113(17):3931–3937. doi:10.1182/blood-2008-10-185256
17. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung C, Park K, Kim WS (2006) Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol: Off J Am Soc Clin Oncol 24(4):612–618. doi:10.1200/jco.2005.04.1384
18. Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, Sun L, Wei L, Li M, Liu C, Zheng J, Liu W, Li G, Chen J (2012) Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol 138(3):429–434. doi:10.1309/ajcp7yltqpusdq5c
19. Huang JJ, Jiang WQ, Lin TY, Huang Y, Xu RH, Huang HQ, Li ZM (2011) Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol: Off J Eur Soc Med Oncol / ESMO 22(1):149–155. doi:10.1093/annonc/mdq314
20. Li YJ, Li ZM, Xia Y, Huang JJ, Huang HQ, Xia ZJ, Lin TY, Li S, Cai XY, Wu-Xiao ZJ, Jiang WQ (2013) Serum C-reactive protein (CRP) as a simple and independent prognostic factor in extranodal natural killer/T-cell lymphoma, nasal type. PLoS ONE 8(5):e64158. doi:10.1371/journal.pone.0064158
21. Lee J, Kim WS, Park YH, Park SH, Park KW, Kang JH, Lee SS, Lee SI, Lee SH, Kim K, Jung CW, Ahn YC, Ko YH, Park K (2005) Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. Br J Cancer 92(7):1226–1230. doi:10.1038/sj.bjc.6602502
22. Lee J, Park YH, Kim WS, Lee SS, Ryoo BY, Yang SH, Park KW, Kang JH, Park JO, Lee SH, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Ko YH, Ahn YC, Park K (2005) Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer (Oxford, England: 1990) 41(10):1402–1408. doi:10.1016/j.ejca.2005.03.010
23. Wang H, Wuxiao ZJ, Zhu J, Wang Z, Wang KF, Li S, Chen X, Lu Y, Xia ZJ (2014) Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study. Leuk Lymphoma:1–7. doi:10.3109/10428194.2014.939964
24. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol: Off J Am Soc Clin Oncol 17(4):1244
25. Siveen KS, Kuttan G (2009) Role of macrophages in tumour progression. Immunol Lett 123(2):97–102. doi:10.1016/j.imlet.2009.02.011
26. Allavena P, Sica A, Solinas G, Porta C, Mantovani A (2008) The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol/Hematol 66(1):1–9. doi:10.1016/j.critrevonc.2007.07.004
27. Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66(2):605–612. doi:10.1158/0008-5472.can-05-4005
28. Ishii H, Takahara M, Nagato T, Kis LL, Nagy N, Kishibe K, Harabuchi Y, Klein E (2012) Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/T-cell lymphoma cells by cell contact-dependent interaction through membrane-bound IL-15. Int J Cancer 130(1):48–58. doi:10.1002/ijc.25969
29. Wang H, Zhu JY, Liu CC, Zhu MY, Wang JH, Geng QR, Lu Y (2015) Increased serum levels of interleukin-15 correlate with negative prognostic factors in extranodal NK/T cell lymphoma. Med Oncol (Northwood, London, England) 32(1):370. doi:10.1007/s12032-014-0370-4
30. Lin ZX, Bai B, Cai QC, Cai QQ, Wang XX, Wu XY, Huang HQ (2012) High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T- and natural killer cell lymphomas. Med Oncol (Northwood, London, England) 29(5):3522–3528. doi:10.1007/s12032-012-0244-6
31. Liu Y, Fan L, Wang Y, Li P, Zhu J, Wang L, Zhang W, Zhang Y, Huang G (2014) Tumor-associated macrophages promote tumor cell proliferation in nasopharyngeal NK/T-cell lymphoma. Int J Clin Exp Pathol 7(9):5429–5435
32. Jiang L, Li P, Wang H, Liu J, Zhang X, Qiu H, Zhang B (2014) Prognostic significance of Ki-67 antigen expression in extranodal natural killer/T-cell lymphoma, nasal type. Med Oncol (Northwood, London, England) 31(10):218. doi:10.1007/s12032-014-0218-y
33. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q (2009) Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114(17):3625–3628. doi:10.1182/blood-2009-05-220285
34. Alvaro T, Lejeune M, Salvado MT, Lopez C, Jaen J, Bosch R, Pons LE (2006) Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol: Off J Am Soc Clin Oncol 24(34):5350–5357. doi:10.1200/jco.2006.06.4766
35. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, Klasa R, Voss N, Connors JM, Gascoyne RD (2005) Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106(6):2169–2174. doi:10.1182/blood-2005-04-1565
36. Kelley T, Beck R, Absi A, Jin T, Pohlman B, Hsi E (2007) Biologic predictors in follicular lymphoma: importance of markers of immune response. Leuk Lymphoma 48(12):2403–2411. doi:10.1080/10428190701665954
37. Hasselblom S, Hansson U, Sigurdardottir M, Nilsson-Ehle H, Ridell B, Andersson PO (2008) Expression of CD68+ tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol Int 58(8):529–532. doi:10.1111/j.1440-1827.2008.02268.x
38. Wada N, Zaki MA, Hori Y, Hashimoto K, Tsukaguchi M, Tatsumi Y, Ishikawa J, Tominaga N, Sakoda H, Take H, Tsudo M, Kuwayama M, Morii E, Aozasa K (2012) Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology 60(2):313–319. doi:10.1111/j.1365-2559.2011.04096.x
39. Nakagawa J, Saio M, Tamakawa N, Suwa T, Frey AB, Nonaka K, Umemura N, Imai H, Ouyang GF, Ohe N, Yano H, Yoshimura S, Iwama T, Takami T (2007) TNF expressed by tumor-associated macrophages, but not microglia, can eliminate glioma. Int J Oncol 30(4):803–811
40. Zhang W, Wang L, Zhou D, Cui Q, Zhao D, Wu Y (2011) Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified. Leuk Lymphoma 52(1):46–52. doi:10.3109/10428194.2010.529204